Barclays Maintains Overweight on Legend Biotech, Raises Price Target to $92
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $90 to $92.
July 21, 2023 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Legend Biotech and raises the price target from $90 to $92, indicating a positive outlook for the company.
The raised price target by Barclays indicates a positive outlook for Legend Biotech. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100